MicroRNAs in Cancer Treatment-Induced Cardiotoxicity

Laura Pellegrini, Sara Sileno, Marco D'Agostino, Eleonora Foglio, Maria Cristina Florio, Vincenzo Guzzanti, Matteo Antonio Russo, Federica Limana, Alessandra Magenta

Research output: Contribution to journalReview articlepeer-review


Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., molecularly targeted therapy and immunotherapy, exhibit a similar frequency and severity of toxicities that range from subclinical ventricular dysfunction to severe cardiomyopathy and, ultimately, congestive heart failure. Specific mechanisms leading to cardiotoxicity still remain to be elucidated. For instance, oxidative stress and DNA damage are considered key players in mediating cardiotoxicity in different treatments. microRNAs (miRNAs) act as key regulators in cell proliferation, cell death, apoptosis, and cell differentiation. Their dysregulation has been associated with adverse cardiac remodeling and toxicity. This review provides an overview of the cardiotoxicity induced by different oncologic treatments and potential miRNAs involved in this effect that could be used as possible therapeutic targets.

Original languageEnglish
Issue number3
Publication statusPublished - Mar 17 2020


Dive into the research topics of 'MicroRNAs in Cancer Treatment-Induced Cardiotoxicity'. Together they form a unique fingerprint.

Cite this